COMPARATIVE EFFICACY OF TEMOBEL AND TEMODAL DRUGS IN MULTIMODALITY TREATMENT OF HIGH-GRADE (III-IV)

Abstract

An open-label, retrospective comparative clinical trial evaluated the efficacy of Temobel (RUP Belmedpreparaty) and Temodal (Schering-Plough, the Office of the Joint-Stock Company «Schering-Plough Central East AG») in 90 patients with high-grade (III-IV) glial brain tumors within a postoperative chemoradiotherapy course (a total target dose of 50-60 Gy). The compared groups, 45 patients in each, were fully matchable in prognostic factors affecting treatment outcomes. Median survival, 1- and 3-year overall survivals with Temobel in the combination treatment scheme were 20 months, 72.7±6.7% and 23.7±9.5%, whereas with Temodal they were 17 months, 77.8±6.2% and 30.3±7.0% respectively (P=0.935). Meanwhile, progressive-free median survival and progressive-free 1- and 3-year survival with Temobel and Temodal were 12 months, 51.0±7.5%, 21.3±6.4% and 11 months, 49.3±7.6%, 15.5±5,7% respectively (P=0.814). No statistically significant differences were found in the survival of patients in the compared groups.